(Received for publication, December 3, 1996, and in revised form, February 4, 1997)
From the Verna and Marrs McLean Department of
Biochemistry and the ¶ Department of Molecular and Human Genetics,
Baylor College of Medicine, Houston, Texas 77030
cDNA encoding the 280-kDa acetyl-CoA carboxylase 2 (ACC2) isoform was isolated from human liver using the polymerase chain reaction. Sequencing the cDNA revealed an open reading frame of 7,449 base pairs (bp) that encode 2,483 amino acids (Mr 279,380). Using 5-kilobase pair cDNA clones as probes, we localized the gene encoding the 280-kDa human carboxylase to chromosome 12q23. When the cDNA of ACC2 was compared with that of ACC1, the nucleotide sequences and the predicted amino acid sequences had about 60 and 80% identity, respectively. Ser77 and Ser79, which were found to be critical for the phosphorylation and subsequent inactivation of rat ACC1 (Ser78 and Ser80 of human ACC1), are conserved in ACC2 and are represented as Ser219 and Ser221, respectively. On the other hand, Ser1200, which is also a phosphorylation site in rat ACC1 (Ser1201 of human ACC1), is not conserved in ACC2. The homology between the amino acid sequences of the two human carboxylases, however, is primarily found downstream of residues Ser78 and Ser81 in human ACC1 and their equivalents, that is Ser219 and Ser221 in ACC2, suggesting that the sequence of the first 218 amino acids at the N terminus of ACC2 represents a unique peptide that accounts, in part, for the variance between the two carboxylases. Using a cDNA probe (400 bp) that encodes the N-terminal amino acid residues of ACC2 in Northern blot analyses of different human and mouse tissues showed that ACC2 is predominantly expressed in liver, heart, and the skeletal muscles. Polyclonal antibodies raised against the N-terminal peptide (amino acid residues 1-220) reacted specifically and equally with human and rat ACC2 carboxylases, confirming the uniqueness of this N-terminal peptide and its conservation in animal ACC2. In addition, we present evidence for the presence of an isoform of ACC2 (Mr 270,000) in human liver that differs from the 280-kDa ACC2 by the absence of 303 nucleotides that encode 101 amino acids in the region between Arg1114 and Asp1215. The regulation and physiological significance of the two ACC2 isoforms remain to be determined.
Acetyl-CoA carboxylase (ACC),1 a biotin-containing enzyme, catalyzes the carboxylation of acetyl-CoA to malonyl-CoA, the rate-limiting step in fatty acid synthesis. Malonyl-CoA is the C2 donor in the de novo synthesis of long chain fatty acids and in their elongation into very long chain fatty acids (1, 2). Malonyl-CoA is also involved in the synthesis of polyketides (3), and there are indications that it may be involved in the synthesis of an as yet unknown compound or pathway (4, 5). Moreover, malonyl-CoA is a regulator of the palmitoyl-CoA-carnitine shuttle system that is involved in the mitochondrial oxidation of long chain fatty acids (6).
ACC is a complex multifunctional enzyme system. In prokaryotes, it is composed of three distinct and separable proteins: the biotin carboxyl carrier protein, the biotin carboxylase, and the transcarboxylase. In eukaryotes, however, the individual proteins of ACC are associated with a single multifunctional polypeptide (Mr 265,000) that is encoded by a single gene. We prefer to refer to this form of ACC as ACC1. The cDNAs coding for the yeast (7), rat (8), chicken (9), and human (10) ACC1 carboxylases have been cloned and sequenced. The predicted amino acid sequences of the ACC1 carboxylases are very similar, there being a greater than 90% identity among the animal ACC1 carboxylases and about 35% similarity between the animal and yeast ACC1 carboxylases. They immunologically cross-react with each other. The ACC1 carboxylases are highly enriched in lipogenic tissues and are under long term control at the transcriptional and translational levels and under short term regulation by the phosphorylation/dephosphorylation of targeted serine residues and by allosteric transformation by citrate or palmitoyl-CoA (11-17). The levels and activities of the ACC1 carboxylase in lipogenic tissues fluctuate in response to both the dietary and hormonal states of the animal. Starvation or diabetes reduces the activity of ACC1 by repressing the transcription of the gene ACC1 or by increasing the phosphorylation levels of the protein ACC1 (or both). On the other hand, refeeding animals, especially a carbohydrate-rich, fat-free diet, or treating diabetic animals with insulin induces the synthesis of the ACC1 carboxylase and increases its activity either by dephosphorylation of the protein or by activation with citrate.
Another carboxylase (ACC2) from rat heart, a tissue in which little or no fatty acid synthesis takes place (18, 19), was discovered in our laboratory by Thampy (20) and purified to a homogeneous state. The ACC2 carboxylase has a molecular weight of 280,000, has biotin as a prosthetic group, and responds to phosphorylation/dephosphorylation and citrate activation in a manner similar to ACC1 (20). Anti-ACC1 antibodies do not significantly inhibit the activity of ACC2, nor do they bind to the protein in a Western blot test (20), suggesting that the two enzymes are different although they catalyze the same reaction and have very similar sequences (see below). These differences were reinforced by the fact that ACC2 is also present at relatively high levels in skeletal muscle (21, 22). Moreover, ACC2 is also found in rat liver (23) and in human liver (this study). Studies with rat liver ACC1 and ACC2 showed that the two isoforms do not cross-react immunochemically although the amino acid sequences of 12 randomly isolated peptides from each carboxylase show a high degree of similarity (~70%) (23).
The physiological role of ACC2 is not clear at this time. Nevertheless, the presence of ACC2 in heart and muscle as the predominant form of carboxylase has led many investigators to propose that ACC2 and its product malonyl-CoA are involved in the regulation of fatty acid oxidation by these tissues (20, 21, 24). Attempts to correlate the rate of fatty acid oxidation in newborn and ischemic hearts with carboxylase activities and malonyl-CoA levels led to the conclusion that fatty acid oxidation in the heart is inversely related to carboxylase activities, a correlation that is compatible with the notion that ACC2 is present in heart and muscle tissues for the purpose of regulating fatty acid oxidation (25, 26). To understand the structure-function of ACC2 and its relationship to ACC1, we isolated ACC2 cDNA from human liver and sequenced it. Herein, we report the complete sequence of the cDNA encoding the human ACC2 carboxylase and the chromosomal localization of its gene. We also show the distribution of ACC2 in various human and mouse tissues and provide evidence for the presence of an isoform of ACC2 in human liver.
Klenow DNA polymerase, T4 polynucleotide kinase,
T4 DNA ligase, and all restriction enzymes were purchased from New
England Biolabs (Beverly, MA). Taq DNA polymerase was
purchased from Perkin-Elmer. The sequencing kits for the dideoxy chain
termination method were purchased from U.S. Biochemical Corp.
32P- or 35S-labeled nucleotides were purchased
from Amersham Corp. Human liver 5-RACE-ready cDNA, human liver
poly(A)+ mRNA, human and mouse multiple-tissue Northern
blots, and the TALON purification system were obtained from Clontech
Laboratories, Inc. Alkaline phosphatase-conjugated secondary
antibodies, nitro blue tetrazolium, and 5-bromo-4-chloro-3-indolyl
phosphate were purchased from Promega, Inc. Reverse transcriptase and
the random primer labeling kit were purchased from Stratagene. The
Western blot kit was from Novagen. All oligonucleotides were
synthesized using a Beckman Oligo 1000 M DNA synthesizer.
All other chemicals used were of the highest quality commercially
available.
Standard molecular biological techniques were employed (27). cDNA clones were sequenced by using the dideoxy chain termination method (28) and a Sequenase T7 DNA polymerase kit. First-strand cDNA was synthesized from poly(A)+ mRNA by reverse transcription with oligo(dT) primers as described (27). Northern analysis was carried out on the human and mouse multiple-tissue blots according to the manufacturer's recommendations.
PCR Quantitation of ACC2 Isoforms in Human LiverGiven the
difficulty in distinguishing, in a Northern blot, between 10-kb
mRNA isoforms that differ in size by only 300 bp, we chose to use
reverse transcriptase-PCR methodology to estimate the quantity of each
human liver ACC2 isoform. Two oligonucleotides, a forward primer
(5-TGGTGCAGTTGGTCCAGAGG-3
(nucleotides 3323-3342)) and a reverse
primer (5
-GGACTCCGACGAATCCCATTCTTG-3
(nucleotides 4444-4467)), were
used in a PCR reaction in which first-strand cDNA from human liver
was used as a template. The PCR products were separated on a 1%
agarose gel and probed with a 427-bp cDNA fragment (nucleotides
3644-4071), which is downstream of the gap and is represented in
both isoforms of ACC2 mRNAs.
Standard metaphase spreads were obtained from the peripheral blood lymphocytes of a human male donor. All of the probes were labeled with biotin-14-dATP (Life Technologies, Inc.) by using nick-translation. The chromosomes were identified by simultaneous 4,6-diamidino-2-phenylindole staining, which produces a Q-banding pattern. Biotinylated DNA was detected by using avidin-conjugated fluorescein isothiocyanate. The details of the fluorescence in situ hybridization procedures and of digital imaging and processing have been reported elsewhere (29, 30).
Cloning and Expression of the N-terminal Region of Human ACC2 cDNAThe cDNA fragment (660 bp) that corresponded to the
N-terminal region of human liver ACC2 carboxylase was amplified by
using PCR techniques. The forward primer
(5-GTCGACGAGCTCGTCTTGCTTCTTTGTC-3
) contained the ATG
translation initiation codon and an SstI linker, and the
reverse primer (5
-CTATGAGGCCGAGCATGTCGCTCGAGAATTG-3
) contained
nucleotides 644-666 plus an XhoI site. The PCR fragment was
digested with SstI and XhoI, subcloned into the
pET32-a plasmid, and expressed as a fusion protein with thioredoxin.
The highly expressed fusion protein was purified on a TALON column
according to the manufacturer's recommendations and was used to raise
polyclonal antibodies in rabbits.
The secondary structure and hydrophobicity of the predicted amino acid sequence of the NH2-terminal region of ACC2 were analyzed (data not shown) by using the peptide structure and plot structure programs in the Genetics Computer Group software package made available to us by the Molecular Biology Computational Resource at Baylor College of Medicine.
Recently, we
reported the complete nucleotide sequence of the 265-kDa human ACC1
cDNA (10). By comparing our sequence with that reported by Ha
et al. (31), we found that the 2.4-kilobase pair cDNA at
the 3-end of their sequence, which was isolated from a human fat
abdominal cDNA library, is not part of the 265-kDa human ACC1
cDNA. Our Northern blot analyses with a PCR fragment we cloned from
human liver cDNA (which was identical to the 3
-terminal sequence
of that reported by Ha et al. (31)) hybridized with an
mRNA of the size (~10 kb) reported for ACC1, suggesting the existence of a second ACC isoform in human liver.
To obtain 5-sequences of this putative second human liver carboxylase,
we used reverse transcriptase-PCR methods. To amplify the different
cDNA fragments, we used first-strand cDNA and 5
-RACE-ready PCR
cDNA from human liver as templates. To isolate the 2.0-kilobase pair 3
-end cDNA (clone g; Fig. 1), we used a
forward primer (5
-AATGAGGTGGGCATGGTGGCC-3
(nucleotides 5371-5391))
based on the published sequence of Ha et al. (31) and a
reverse primer (5
-GACAGCCCGGCCTCCACCTGA-3
(nucleotides 7432-7452)).
Amplification reactions were carried out on a PTC-100 programmable
thermal controller (MJ Research, Inc.) by varying the time and
temperature as follows: 94 °C for 1 min, 55 °C for 1 min, and
72 °C for 3 min, followed by a 10-min elongation step at 72 °C.
The amplified PCR products were then separated by agarose gel
electrophoresis. The bands with the expected size were extracted,
treated with T4 polynucleotide kinase, and subcloned into the
SmaI or EcoRV restriction site of pBluescript II
KS+ vector (Stratagene). The subcloned cDNA fragments were sequenced from both ends by using T7 DNA polymerase kits. Although the
sequence of clone g was identical to that of the abdominal fat ACC
cDNA, it had less than 60% identity at the nucleotide level with
its counterpart of the human ACC1 cDNA (10).
To extend the 5-end of clone g (Fig. 1), we used first-strand cDNA
and RACE-ready PCR cDNA synthesized from commercially available
human liver poly(A)+ mRNA (Clontech) as a template.
Briefly, a single-stranded anchor oligonucleotide
(5
-CACCTTTCGCATTGGTAGGTTTGGCCC-3
(nucleotides 5460-5486))
that was ligated to the 5
-end of human liver cDNA was used as the
forward primer, and a second oligonucleotide
(5
-GGGCCAAAGGATCCAATGCGAAAGGTG-3
), corresponding to the
5
-end of clone g (Fig. 1), was used as the reverse primer. Several
overlapping clones, each ranging from 500 to 1,000 bp in size, were
isolated, subcloned, and sequenced. Clone f contained the longest
cDNA fragment (Fig. 1). Clones d and e (Fig. 1), each of which
contained the highly conserved biotin-binding site, were isolated with
a degenerate forward primer (5
-ATNGANGTNATGAA(A/G)ATG-3
) that was
based on the sequence of human ACC1 (10), which includes the
Met-Lys-Met codons at the 3
-end, and a reverse primer
(5
-CCGACGAATCCCATTCTTG-3
(nucleotides 4449-4467)) from clone f (Fig.
1). Using these two primers and first-strand cDNA as a template, we
amplified two cDNA fragments, one 1.6 kb in length (clone d) and
the other 1.3 kb in length (clone e) (Fig. 1). Subcloning and
sequencing these two fragments revealed that their sequences are
identical. However, 303 nucleotides that encode 101 amino acids are
present in the 1.6-kb fragment but absent from the 1.3-kb fragment.
To extend our cloning upstream of clones d and e, we used the same
cloning strategy employed above. In this case, however, we prepared a
degenerate forward primer (5-TCNCC(A/C)GCNGA(A/G)TT(T/C)GTNAC-3
) that
was based on the amino acid sequence of peptide 17, which was reported
by Winz et al. (23) and was present in both the rat ACC1 and
ACC2 isoforms. Using this primer together with a reverse primer
(5
-CCTTCTAAAGTCCACCCGGCTGAA-3
(nucleotides 2890-2913)) derived from
clone d, we amplified a 2.1-kilobase pair cDNA fragment (clone c;
Fig. 1). Nucleotide sequencing of this clone revealed a high degree of
similarity with the corresponding region of the human ACC1 cDNA.
Finally, two overlapping cDNA clones, a (900 bp) and b (950 bp),
which extended upstream of the first Met codon, were obtained by using
the 5
-RACE-ready PCR cDNA technique used above with a reverse
primer (5
-GGTTTGTTCGCATGGTGACCCCC-3
(nucleotides 878-900)) derived
from clone c. Both clones contained sequences from the 5
-untranslated
region and the first ATG, which was preceded by two TGA stop codons,
suggesting that this ATG is the first translation codon.
The nucleotide sequence of the cDNA of the human liver
ACC2 carboxylase has an open reading frame of 7,449 nucleotides (Fig. 2) that encode 2,483 amino acids with a calculated
molecular weight of 279,330, which is close to the 280-kDa mass
estimated for the carboxylase isoform isolated from rat heart, skeletal
muscle, and liver (20, 21) and from human liver. We readily identified the highly conserved biotin-binding site (Met-Lys-Met), the putative ATP-binding site of the biotin-carboxylase partial activity, and the
CoA-binding site of the transcarboxylase partial domain (Fig. 2). The
amino acid sequences at these sites are conserved in the ACC1
carboxylases of human liver (10), rat liver (8), chicken liver (9), and
yeast (7) and are more likely to also be conserved among ACC2
carboxylases. Comparisons of the nucleotide and deduced amino acid
sequences of the human ACC2 cDNA with that of the human ACC1
cDNA showed about 60 and 75% identity, respectively. Alignment of
the amino acid sequences of human ACC1 and ACC2 clearly showed that the
extra 142 amino acids in ACC2 (426 bp in ACC2 cDNA), which account
for the main difference in molecular weight between the 265-kDa ACC1
and 280-kDa ACC2, are located at the NH2-terminal end of
ACC2 (Fig. 3). Moreover, the amino acid sequences in the
NH2-terminal region of the ACC2 polypeptide have no
homology with those of human ACC1 or rat ACC1. The identity of the
amino acid sequences at the NH2-terminal end of both
carboxylases begins near Ser78 (nucleotides 232-234)
in human ACC1 and near Ser219 (nucleotides 655-657) in
ACC2 and continues downstream of these serine residues, but not
upstream of them, as shown in Fig. 3. Ser78 and
Ser80 in human ACC1 (10) are equivalent to
Ser77 and Ser79 of rat liver ACC1 that were
found to be critical in the activation/inactivation of rat ACC1 due to
phosphorylation (12). These serine residues are conserved in ACC2 as
Ser219 and Ser221, as evidenced by the high
degree of similarity in the amino acid sequences between ACC1 and ACC2
at and immediately downstream from these serines (Fig. 3). However,
Ser1200 of rat ACC1 (Ser1201 of human ACC1
(10)), which has been implicated in the phosphorylation and regulation
of ACC1 (12), apparently is not conserved in human ACC2 (Fig. 3). In
fact, the amino acid sequences in this region show that there is little
similarity between the two ACC isoforms and that some amino acids in
the ACC1 polypeptide are deleted from ACC2 (Fig. 3).
As discussed above, during the cloning of the full-length human liver
ACC2 cDNA, we isolated two cDNA clones, d (1.6 kb) and e (1.3 kb) (Fig. 1), that had identical sequences, except that the shorter
clone lacked the 303 nucleotides that encode 101 amino acids between
Arg1114 and Asp1215 (Fig. 2). The complete
identity between the nucleotide sequences of the two clones in the
overlapping regions suggests that these clones are the product of an
alternate splicing mechanism and may represent two ACC2 isoforms, one
280 kDa and the other 270 kDa. To rule out a cloning artifact and to
estimate the abundance of both ACC2 mRNA isoforms, we used reverse
transcriptase-PCR methods (32) and Southern blot analysis as stated
under "Experimental Procedures." As expected, we amplified two
cDNA fragments, 1.1 and 0.8 kb (Fig. 4, lane
2). Using the 400-bp cDNA fragment located downstream of
Asp1215 as a probe in Southern blot analysis and scanning
the intensities of the blots showed that the 280-kDa ACC2 isoform is
three times more abundant than the 270-kDa isoform (Fig. 4, lane
3). At this stage, we cannot rule out other differences between
the sequences of the 280- and 270-kDa isoforms. We were unable,
however, to isolate other cDNA clones that had such differences in
their sequences. Comparing the peptide of the 101 amino acids that are
missing from the 270-kDa ACC2 isoform with its counterpart in ACC1
showed a high degree of sequence identity except for a segment of a
polypeptide of 30 amino acids that are absent in ACC1 (Fig. 3).
Expression of ACC2 in Various Human and Mouse Tissues
Using
the 400-bp PCR clone that encodes the N-terminal region of ACC2 as a
specific probe for ACC2, we performed Northern blot analyses of
mRNAs from various human and mouse tissues. Our results showed that
the probes hybridized to a major (~10-kb) mRNA band and to a
smaller (9-kb) band (Fig. 5). We believe that the
shorter band does not represent the 270-kDa ACC isoform, because both
bands hybridized with the 300-bp PCR fragment that is present in clone
d but not in clone e (data not shown). The two bands, therefore, may
represent transcripts that differ in the noncoding region. The 400-bp
cDNA probe hybridized to the mRNAs of ACCs from human and mouse
hearts, livers, and skeletal muscles and was expressed in a similar
pattern (Fig. 5), suggesting that ACC2 is conserved in human and mouse
tissues. In comparing the muscle tissues of human organs, the heart and
skeletal muscle have higher levels of ACC2 mRNA (Fig.
5B). The high levels of ACC2 mRNA in heart and muscle
tissues are consistent with the earlier findings of high levels of ACC2
in rat heart and muscle (20, 33).
Chromosomal Localization of the ACC2 Gene
Previously, we
mapped the gene that encodes human ACC1 to chromosome 17q21 (10). When
we compared the cDNA sequences of the 265- and 280-kDa ACC
isoforms, it became apparent that they most probably are not products
of the differential splicing of a single gene. To localize the gene
that encodes the 280-kDa human ACC, we performed fluorescence in
situ hybridization of a biotin-labeled cDNA probe (5 kb) to
normal human metaphase chromosomes. Hybridization of this probe
resulted in specific labeling of only chromosome 12q23.1 (Fig.
6). These results are the first direct evidence that the
265- and 280-kDa human ACC isoforms are the products of two separate
genes, ACC1 and ACC2, respectively, and,
therefore, rule out the alternative splicing hypothesis.
Expression of the N-terminal cDNA in Escherichia coli and Preparation of Specific Polyclonal Antibodies
To produce
polyclonal antibodies that would recognize only the ACC2 protein, we
cloned a cDNA fragment (nucleotides 1-666) that encodes the
N-terminal variant region of ACC2 into the PET plasmid and expressed it
in BL21 E. coli as a thioredoxin fusion protein (Fig.
7). The soluble fusion protein was purified using a
TALON affinity column and eluted with 100 mM imidazole. The highly purified fusion protein (Fig. 7C) was used to raise
antibodies in rabbits. These polyclonal antibodies recognized human
ACC2 but not human ACC1 (data not shown). They also cross-reacted with rat liver ACC2 but not with the more abundant rat liver ACC1 as shown
in a Western blot (Fig. 8, lane 3). These
results, together with the Northern blot analyses of mRNAs of human
and mouse tissues displayed in Fig. 5, clearly show that this ACC
isoform is highly conserved at both the nucleotide and the amino acid
levels and is expressed in a tissue-specific manner. Interestingly,
antibodies raised against human ACC1 purified from HeLa cells
recognized rat liver ACC1 but not rat liver ACC2, despite the high
degree of homology between the two proteins (Fig. 8). Similar
observations were made by Thampy (20) and by Witters et al.
(33), who reported that antibodies raised against the 265-kDa rat liver
ACC did not recognize the 280-kDa rat ACC isoform. As expected, both
ACC1 and ACC2 reacted strongly with avidin peroxidase, indicating that they are indeed biotin-containing enzymes (Fig. 8, lane
4).
It has long been suggested that the multiple forms of ACC detected by SDS-PAGE are the products of limited proteolysis or occur as the result of differential splicing mechanisms. Although it is nearly impossible to isolate only one form of ACC from animal tissues, several lines of evidence indicated the existence of at least two ACC isoforms, the 265-kDa (ACC1) and the 280-kDa (ACC2). Although both ACC1 and ACC2 contain covalently bound biotin as the prosthetic group, ACC1 is immunologically distinct from ACC2 (20, 21, 33). The two isoforms also exhibit different kinetics toward the substrate acetyl-CoA (33). The data reported herein, including the chromosomal localization, provide the first direct evidence that ACC1 and ACC2 are the products of two separate genes.
Comparing the predicted amino acid sequences of ACC1 and ACC2 showed the presence of an additional 142 amino acids at the NH2 terminus of ACC2 that may account for the difference in molecular weight and may be involved in targeting the ACC2 protein toward a specified cellular membrane or membranes. Examination of the hydropathic profile of the predicted amino acid sequence of the NH2-terminal region of ACC2 (residues 1-140) by using the Kyte-Doolittle algorithm (34) and of the secondary structure predicted according to the Chou-Fasman algorithm (35) showed that the peptide comprising the first 20 amino acids was remarkably hydrophobic in character and that a second set of sequences (residues 50-100) was highly hydrophilic in character. The hydrophobic character of the lead peptide suggests that ACC2 may be a membrane-targeted or -bound enzyme. The association of ACC2 with cellular membranes (mitochondrial, nuclear, and endoplasmic) may reflect its function within the cell. At this time, however, the physiological significance of the 280-kDa ACC2 and its 270-kDa isoform is not clear. Nevertheless, all available evidence suggests a role for ACC2 in the regulation of fatty acid oxidation. The presence of ACC2 in nonlipogenic tissues such as heart and skeletal muscle, in which very little fatty acid synthesis occurs but in which there are very high levels of fatty acid oxidation, is presumed to catalyze the synthesis of malonyl-CoA, a potent inhibitor of the carnitine palmitoyltransferase 1 system and thereby to regulate mitochondrial fatty acid oxidation.
The heart derives its energy primarily from the oxidation of fatty
acids and carbohydrates. The consumption and balance between the
utility of the two substrates becomes important to the function of the
heart. Since -oxidation of fatty acids utilizes CoA as a substrate
and yields acetyl-CoA as a product, as does the oxidation of pyruvate
via the pyruvate dehydrogenase complex, the mitochondrial acetyl-CoA:CoA ratio becomes a factor in influencing the activities of
the two pathways.
-Oxidation of fatty acids results in an increase
in the acetyl-CoA:CoA ratio, leading to a decrease in the activity of
the pyruvate dehydrogenase complex that then results in a decrease in
carbohydrate oxidation (24, 36). Conversely, stimulating glucose
oxidation by increasing the activity of the pyruvate dehydrogenase
complex by, for example, dichloroacetate (37), leads to an increase in
the acetyl-CoA:CoA ratio and a decrease in fatty acid oxidation by the
mitochondria (38). These results could be explained by the inhibition
of thiolase activity resulting from an increase in the
intramitochondrial concentration of acetyl-CoA (39). However, the
presence of ACC2 in heart and muscle tissues and the role of its
product malonyl-CoA in regulating carnitine palmitoyltransferase 1 activity suggested a role for carnitine and ACC2 in regulating the
oxidation of fatty acids and carbohydrates by heart and muscle. In this
role, carnitine is a substrate of the carnitine palmitoyltransferase 1 system that shuttles long chain fatty acyl groups across the
mitochondrial membrane. Carnitine also is involved in the export of
acetyl-CoA from the mitochondria to the cytosol via the carnitine
acetyltransferase. Thus, the presence of carnitine would decrease the
intramitochondrial acetyl-CoA:CoA ratio by translocating the acetyl-CoA
from the mitochondria to the cytosol, where it is converted by ACC2
into malonyl-CoA, a potent but reversible inhibitor of carnitine
palmitoyltransferase 1 (Ki = 50 nM (40,
41)), and thereby decreasing the fatty acyl substrate available for
-oxidation. In this scheme, ACC2 and carnitine acetyltransferase are
key players in the regulation of fatty acid and carbohydrate oxidation
in the heart.
Alternatively, ACC2 may also be important in the heart and muscle by providing malonyl-CoA for the elongation of fatty acids into very long chain acids that are required for the structure of the cellular membrane. Another possibility is that malonyl-CoA is required for the synthesis of as yet unknown compounds (possibly a polyketide) or in a metabolic pathway that is needed for cell viability, much as ACC is essential for the growth and viability of yeast cells (4, 5) or, in the case of fission yeast, in the structure-function of the nuclear membrane and division and separation of the nucleus (42, 43).
The nucleotide sequence(s) reported in this paper has been submitted to the GenBankTM/EMBL Data Bank with accession number(s) U89344[GenBank].
We thank the Molecular Biology Computational Resource at Baylor College of Medicine for providing access to the computer programs we used for the sequence analysis. We also thank Pamela Paradis Powell for editing the manuscript.